Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma
News 08.01.2018 Molecular Partners AG announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM). Eight patients have been treated in the first cohort of 8 mg/kg MP0250 and were included in the safety analysis set. No dose-limiting toxicities (DLTs) have been reported to date....